Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact

Citations to this article

Hello, goodbye
Andrew R. Marks
Andrew R. Marks
Published February 1, 2007
Citation Information: J Clin Invest. 2007;117(2):280-281. https://doi.org/10.1172/JCI31214.
View: Text | PDF
Editorial

Hello, goodbye

  • Text
  • PDF
Abstract

Much has changed in the 5 years since the responsibility for editing the JCI was transferred to Columbia University. Wars and a hurricane have conspired with other factors to overwhelm the national treasury. Support for investigator-initiated research at the NIH is now at a level that jeopardizes the nation’s ability to adequately train future scientists to maintain the country’s leadership in biomedical research. Indeed, there is insufficient support for even the best and brightest biomedical scientists to pursue the frontiers of the sciences at a time of unprecedented opportunities. Human embryonic stem cell research is still being suppressed in the United States. Economic models that enable academic health centers to flourish in the face of increasing challenges and the rising costs of health care have for the most part remained elusive. Translational research has become the buzzword, but there is widespread confusion and disagreement about how to do it. Despite all of these and other challenges to the biomedical research enterprise, the JCI remains vibrant, with record numbers of submissions and a loyal and enthusiastic readership.

Authors

Andrew R. Marks

×

Loading citation information...
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts